| Cat.No. | Name | Information |
|---|---|---|
| M1641 | Quizartinib (AC220) | Quizartinib (AC220) is a uniquely potent and selective FLT3 inhibitor. |
| M7527 | Gilteritinib | Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. |
| M43515 | FLT3-IN-19 | FLT3-IN-19 is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM. |
| M43514 | LT-540-717 | LT-540-717 is a potent FLT3 inhibitor (IC50=0.62 nM) with antiproliferative activity. |
| M43513 | GTP-14564 | GTP-14564 is a tyrosine kinase inhibitor targeting to internal tandem duplication (ITD) and FLT3. |
| M43512 | HDAC-IN-63 | HDAC-IN-63 is a dual FLT3/HDAC inhibitor (IC50: 0.844 and 30.0 nM for FLT3 and HDAC1 respectively). |
| M43511 | FLT3-IN-20 | FLT3-IN-20 is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. |
| M40752 | Quizartinib hydrochloride | Quizartinib hydrochloride is a FLT3 inhibitor with IC50 values of 1.1 nM for Flt3-ITD and 4.2 nM for Flt3-WT, and is 10-fold more selective for Flt3 than for KIT, PDGFRA, PDGFRB, RET, and CSF-1R. It can be used in studies related to acute myeloid leukemia (AML). |
| M31079 | BPR1J-097 Hydrochloride | BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11 nM. |
| M30770 | TTT 3002 | TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research. |
| M30706 | JI6 | JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia. |
| M29644 | BPR1K871 | BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy. |
| M29490 | FLT3-IN-4 | FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia. |
| M29485 | Tuspetinib | Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells. |
| M29479 | FLT3/ITD-IN-4 | FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC50 of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research. |
| M29420 | HP1328 | HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia. |
| M28236 | OTS447 | OTS447 is a potent FLT3 inhibitor with an IC50 of 21 nM (WO2012016082A1, compound 335). |
| M28176 | BPR1J-097 | BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM. |
| M20679 | SKLB4771 (FLT3-IN-1) | SKLB4771 is a potent and selective inhibitor of human receptor-type tyrosine-protein kinase FLT3 with IC50 of 10 nM. |
| M20359 | WAY-304191 | WAY-304191 is a CXCR3 antagonist. |
| M20307 | WAY-663387 | WAY-663387 is a FLT3 kinase inhibitor. |
| M20061 | WAY-297342 | WAY-297342 is a inhibitor of Influenza Virus Polymerase |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
